Cellular Biomedicine Group Company Profile (NASDAQ:CBMG)

About Cellular Biomedicine Group (NASDAQ:CBMG)

Cellular Biomedicine Group, Inc. (CBMG) is a biomedicine company. The Company is engaged in the development of treatments for cancerous and degenerative diseases utilizing cell-based technologies. The Company operates in Biomedicine Cell Therapy segment. The Company's technology includes platforms, such as Immune Cell therapy for treatment of broad range of cancers using Vaccine, T Cells Receptor (TCR) clonality analysis technology and T Central Memory Cell (Tcm) preparation methodologies, Chimeric Antigen Receptor T cell (CAR-T), and human adipose-derived mesenchymal progenitor cells (haMPC) for treatment of joint and autoimmune diseases, with primary research and manufacturing facilities in China. It is focused on developing and marketing cell-based therapies based on its cellular platforms, to treat serious chronic and degenerative diseases, such as cancer, orthopedic diseases, including osteoarthritis and tissue damage, various inflammatory diseases and metabolic diseases.

Industry, Sector and Symbol:

Sector: Medical
Industry: Biotechnology
Sub-Industry: N/A
Symbol: NASDAQ:CBMG
CUSIP: N/A
Web: www.cellbiomedgroup.com

Capitalization:

Market Cap: $88.6 million
Outstanding Shares: 14,290,000

Average Prices:

50 Day Moving Avg: $9.43
200 Day Moving Avg: $11.78
52 Week Range: $5.05 - $15.69

P/E:

Trailing P/E Ratio: N/A
Foreward P/E Ratio: -3.35
P/E Growth: 0.00

Sales & Book Value:

Annual Revenue: $237,864.00
Price / Sales: 372.47
Book Value: $4.29 per share
Price / Book: 1.45

Profitability:

EBIDTA: ($22,090,000.00)
Net Margins: -2,272.04%
Return on Equity: -36.06%
Return on Assets: -34.25%

Debt:

Current Ratio: 23.61%
Quick Ratio: 23.48%

Misc:

Average Volume: 29,178 shs.
Beta: 2.86
Short Ratio: 21.11

Frequently Asked Questions for Cellular Biomedicine Group (NASDAQ:CBMG)

What is Cellular Biomedicine Group's stock symbol?

Cellular Biomedicine Group trades on the NASDAQ under the ticker symbol "CBMG."

How were Cellular Biomedicine Group's earnings last quarter?

Cellular Biomedicine Group Inc (NASDAQ:CBMG) posted its earnings results on Tuesday, March, 14th. The company reported ($0.43) earnings per share for the quarter, hitting analysts' consensus estimates of ($0.43). The company earned $0.06 million during the quarter. Cellular Biomedicine Group had a negative return on equity of 36.06% and a negative net margin of 2,272.04%. View Cellular Biomedicine Group's Earnings History.

Where is Cellular Biomedicine Group's stock going? Where will Cellular Biomedicine Group's stock price be in 2017?

1 analysts have issued 12-month target prices for Cellular Biomedicine Group's shares. Their predictions range from $18.00 to $18.00. On average, they anticipate Cellular Biomedicine Group's stock price to reach $18.00 in the next year. View Analyst Ratings for Cellular Biomedicine Group.

Are investors shorting Cellular Biomedicine Group?

Cellular Biomedicine Group saw a increase in short interest during the month of April. As of April 28th, there was short interest totalling 344,340 shares, an increase of 3.3% from the April 13th total of 333,393 shares. Based on an average daily volume of 14,519 shares, the days-to-cover ratio is presently 23.7 days.

Who are some of Cellular Biomedicine Group's key competitors?

Some companies that are related to Cellular Biomedicine Group include VBI Vaccines, Inc. - (VBIV), Peregrine Pharmaceuticals (PPHM), Genocea Biosciences (GNCA), RedHill Biopharma Ltd - (RDHL), Strongbridge Biopharma plc (SBBP), Novelion Therapeutics (NVLN), Trevena (TRVN), Foamix Pharmaceuticals Ltd (FOMX), Athersys (ATHX), MannKind (MNKD), Mediwound Ltd (MDWD), Vascular Biogenics Ltd (VBLT), Recro Pharma (REPH), Uniqure NV (QURE), Oncomed Pharmaceuticals (OMED), Evogene Ltd (EVGN), Fate Therapeutics (FATE) and Conatus Pharmaceuticals (CNAT).

How do I buy Cellular Biomedicine Group stock?

Shares of Cellular Biomedicine Group can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

How much does a share of Cellular Biomedicine Group stock cost?

One share of Cellular Biomedicine Group stock can currently be purchased for approximately $6.20.

Consensus Ratings for Cellular Biomedicine Group (NASDAQ:CBMG) (?)

Ratings Breakdown:	1 Buy Rating
Consensus Rating:	Buy (Score: 3.00)
Consensus Price Target:	$18.00 (190.32% upside)

Analysts' Ratings History for Cellular Biomedicine Group (NASDAQ:CBMG)

Show:

Date	Firm	Action	Rating	Price Target	Impact on Share Price	Details
5/15/2017	Maxim Group	Set Price Target	Buy	$18.00	High

(Data available from 5/26/2015 forward)

Earnings History for Cellular Biomedicine Group (NASDAQ:CBMG)

Earnings by Quarter for Cellular Biomedicine Group (NASDAQ:CBMG)

Earnings History by Quarter for Cellular Biomedicine Group (NASDAQ:CBMG)

Date	Quarter	Consensus Estimate	Actual EPS	Revenue Estimate	Actual Revenue	Release Link	Conference Call
3/14/2017	Q4 2016	($0.43)	($0.43)		$0.06 million	View	N/A
8/9/2016	Q216		($0.52)		$0.07 million	View	N/A
3/14/2016	Q415	($0.42)	($0.43)	$1.50 million	$0.62 million	View	N/A
11/13/2015	Q3	($0.43)	($0.44)		$0.63 million	View	N/A
8/14/2015	Q215	($0.37)	($0.44)		$0.66 million	View	N/A
5/18/2015	Q115	($0.40)	($0.39)		$0.60 million	View	N/A
3/31/2015		($0.32)	($0.57)			View	N/A

(Data available from 1/1/2011 forward)

Earnings Estimates for Cellular Biomedicine Group (NASDAQ:CBMG)

Current Year EPS Consensus Estimate: $-1.80 EPS
Next Year EPS Consensus Estimate: $-1.85 EPS

Dividend History for Cellular Biomedicine Group (NASDAQ:CBMG)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trading and Institutional Ownership History for Cellular Biomedicine Group (NASDAQ:CBMG)

Insider Ownership Percentage: 7.30%
Institutional Ownership Percentage: 9.01%

Insider Trades by Quarter for Cellular Biomedicine Group (NASDAQ:CBMG)

Transaction Date	Insider Name	Title	Buy/Sell	Number of Shares	Average Share Price	Total Transaction
2/22/2016	Andrew K Chan	SVP	Sell	1,307	$18.22	$23,813.54
2/17/2016	Andrew K. Chan	SVP	Sell	1,516	$17.76	$26,924.16
1/21/2016	Andrew K. Chan	SVP	Sell	2,812	$12.90	$36,274.80
12/21/2015	Andrew K. Chan	SVP	Sell	12,812	$21.94	$281,095.28
11/23/2015	Andrew K. Chan	SVP	Sell	5,332	$20.64	$110,052.48
10/21/2015	Wei (William) Cao	CEO	Sell	20,000	$19.59	$391,800.00
10/20/2015	Andrew K. Chan	SVP	Sell	5,215	$20.20	$105,343.00
9/21/2015	Andrew K. Chan	SVP	Sell	27,927	$20.80	$580,881.60
12/23/2014	Pak To Leung	Major Shareholder	Sell	142,857	$14.00	$1,999,998.00
6/26/2014	David Bolocan	Director	Buy	10,000	$5.00	$50,000.00
5/22/2014	Tony Liu	CFO	Buy	100,000	$5.00	$500,000.00
7/23/2013	Keith Wong	Director	Sell	320,050	$0.13	$41,606.50

(Data available from 1/1/2013 forward)

Headline Trends for Cellular Biomedicine Group (NASDAQ:CBMG) Latest Headlines for Cellular Biomedicine Group (NASDAQ:CBMG)

Source:

Date	Headline
	Cellular Biomedicine Group Inc (CBMG) Short Interest Up 3.3% in April www.americanbankingnews.com - May 23 at 7:04 AM
	Cellular Biomedicine Group (CBMG) Announces Publication Titled “Target cell killing effects of CD20 www.nasdaq.com - May 19 at 8:52 AM
	Cellular Biomedicine Group (CBMG) Announces Publication Titled “Target cell killing effects of CD20 targeting chimeric antigen receptor T cells derived from the type II anti-CD20 antibody” in Conjunction with 2017 ASCO Annual Meeting finance.yahoo.com - May 19 at 8:52 AM
	Cellular Biomedicine Group Inc (CBMG) Given a $18.00 Price Target by Maxim Group Analysts www.americanbankingnews.com - May 15 at 5:02 PM
	BRIEF-Cellular Biomedicine adds second clinical site in the expansion of CAR-T Phase I clinical trial www.reuters.com - May 15 at 3:53 PM
	Cellular Biomedicine Group (CBMG) Announces the Addition of a Second Clinical Site in the Expansion of its Chimeric Antigen Receptor T-cell (CAR-T) Phase I Clinical Trial for Its CARD-1 Trial in Patients with Non-Hodgkin Lymphoma (NHL) finance.yahoo.com - May 15 at 11:44 AM
	Maxim Group Analysts Give Cellular Biomedicine Group Inc (CBMG) a $18.00 Price Target www.americanbankingnews.com - May 10 at 12:16 AM
	BRIEF-Cellular Biomedicine Q1 net loss per share $0.43 www.reuters.com - May 8 at 9:06 PM
	Cellular Biomedicine reports 1Q loss marketbeat.com - May 8 at 5:36 PM
	Cellular Biomedicine Group Reports First Quarter 2017 Financial Results and Provides Business Highlights finance.yahoo.com - May 8 at 4:05 PM
	Cellular Biomedicine Group (CBMG) Getting Favorable Media Coverage, AlphaOne Reports www.americanbankingnews.com - May 3 at 12:20 AM
	Cellular Biomedicine Group Announces Results of 2017 Annual Meeting of Stockholders finance.yahoo.com - May 1 at 4:10 PM
	Cellular Biomedicine Group (CBMG) Earns Media Sentiment Rating of 0.48 www.americanbankingnews.com - April 28 at 11:54 AM
	Cellular Biomedicine Group (CBMG) Getting Positive Press Coverage, Report Finds www.americanbankingnews.com - April 25 at 10:32 AM
	Cellular Biomedicine Group (CBMG) Given Coverage Optimism Score of 0.46 www.americanbankingnews.com - April 18 at 1:38 PM
	Cellular Biomedicine Group (CBMG) Receiving Positive Media Coverage, Report Finds www.americanbankingnews.com - April 15 at 9:21 AM
	GE Collaborates with CBMG to Enhance Healthcare Portfolio finance.yahoo.com - April 11 at 10:05 AM
	Cellular Biomedicine and GE Healthcare Ink Pact finance.yahoo.com - April 10 at 4:07 PM
	Maxim Group Reiterates Buy Rating for Cellular Biomedicine Group Inc (CBMG) www.americanbankingnews.com - April 10 at 1:42 PM
	Cellular Biomedicine Group (CBMG) Announces Completion of Wuxi GMP Facility Expansion finance.yahoo.com - March 30 at 4:35 PM
	Is Cellular Biomedicine Group A Buy? seekingalpha.com - March 26 at 10:49 AM
	Cellular Biomedicine Group (CBMG) Announces Annual Meeting of Stockholders finance.yahoo.com - March 21 at 9:15 AM
	BRIEF-Cellular Biomedicine had working capital of $38.3 mln as of Dec. 31 www.reuters.com - March 15 at 2:06 AM
	CELLULAR BIOMEDICINE GROUP, INC. Files SEC form 10-K/A, Annual Report biz.yahoo.com - March 14 at 9:04 PM
	CELLULAR BIOMEDICINE GROUP, INC. Files SEC form 10-K, Annual Report us.rd.yahoo.com - March 14 at 11:12 AM
	Cellular Biomedicine Group Reports Full-Year 2016 Financial Results and Recent Operational Progress us.rd.yahoo.com - March 14 at 11:12 AM
	Exclusive: CBMG CEO Talks Stem-Cell Therapies, Cancer Treatments, Financials & The Chinese Market www.benzinga.com - March 4 at 1:35 AM
	Cellular Biomedicine Group Awarded $2.29 Million Grant from the California Institute for Regenerative Medicine (CIRM) to Fund AlloJoin™ Allogeneic Stem Cell Therapy for Knee Osteoarthritis (KOA) in the U.S. us.rd.yahoo.com - March 1 at 10:29 AM
	Cellular Biomedicine Group (CBMG) Presents at 19th Annual BIO CEO & Investor Conference seekingalpha.com - February 15 at 2:52 AM
	Cellular Biomedicine Group (CBMG) to Present at the 19th BIO CEO & Investor Conference on February www.nasdaq.com - February 8 at 3:18 AM
	Cellular Biomedicine Group (CBMG) to Present at the 19th BIO CEO & Investor Conference on February 13, 2017 feeds.benzinga.com - February 7 at 9:19 AM
	Cellular Biomedicine Group (CBMG) Gains Approval to Commence Phase I Trial for C-CAR011 in China www.streetinsider.com - January 9 at 10:21 PM
	Cellular Biomedicine Group (CBMG) Approved to Commence Phase I Trial (CALL-1) for C-CAR011 in Adult www.nasdaq.com - January 9 at 10:21 PM
	Cellular Biomedicine Group (CBMG) Approved to Commence Phase I Trial (CALL-1) for C-CAR011 in Adult Patients with Relapsed or Refractory B-cell Acute Lymphoblastic Leukemia (ALL) in China us.rd.yahoo.com - January 9 at 9:00 AM
	Cellular Biomedicine Group (CBMG) to Present at the 9th Annual Biotech Showcase in San Francisco finance.yahoo.com - January 4 at 5:11 PM
	Cellular Biomedicine Group (CBMG) Expands Cell Production With Capacity to Produce CAR-T Therapies to Treat 10,000 Cancer Patients Annually finance.yahoo.com - January 3 at 11:05 AM
	8:00 am Cellular Biomedicine announces three-month interim safety data from Phase I Clinical Trial for AlloJoin off-the-shelf allogeneic stem cell therapy for knee osteoarthritis us.rd.yahoo.com - December 10 at 11:39 AM
	Cellular Biomedicine Group Announces Three-Month Interim Safety Data from Phase I Clinical Trial for AlloJoin™ Off-the-Shelf Allogeneic Stem Cell Therapy for Knee Osteoarthritis finance.yahoo.com - December 9 at 4:27 PM
	CELLULAR BIOMEDICINE GROUP, INC. Files SEC form 8-K, Regulation FD Disclosure biz.yahoo.com - December 8 at 4:56 PM
	Cellular Biomedicine Group (CBMG) Approved to Commence Phase I Trial (CARD-1) for C-CAR011 in Patients … finance.yahoo.com - November 30 at 7:01 AM
	Cellular Biomedicine Group (CBMG) Approved to Commence Phase I Trial (CARD-1) for C-CAR011 in Patients with Refractory Diffuse Large B-cell Lymphoma (DLBCL) in China finance.yahoo.com - November 30 at 7:01 AM
	CELLULAR BIOMEDICINE GROUP, INC. Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits biz.yahoo.com - November 30 at 7:01 AM
	CELLULAR BIOMEDICINE GROUP, INC. Files SEC form 8-K, Change in Directors or Principal Officers, Financial Statements biz.yahoo.com - November 15 at 10:44 AM
	Cellular Biomedicine Group Announces Appointment of Ant Financial Vice President, Gang Ji, to the Board of Directors finance.yahoo.com - November 14 at 4:13 PM
	CELLULAR BIOMEDICINE GROUP, INC. Files SEC form 10-Q, Quarterly Report biz.yahoo.com - November 8 at 2:49 PM
	CELLULAR BIOMEDICINE GROUP, INC. Files SEC form 8-K, Amendments to Articles of Inc. or Bylaws; Change in Fiscal Year, biz.yahoo.com - September 22 at 9:45 AM
	Coverage initiated on Cellular Biomedicine by Maxim Group finance.yahoo.com - September 22 at 9:45 AM
	Cellular Biomedicine Group Announces Results of 2016 Annual General Meeting finance.yahoo.com - September 10 at 8:48 AM
	CELLULAR BIOMEDICINE GROUP, INC. Files SEC form 8-K, Submission of Matters to a Vote of Security Holders, Regulation biz.yahoo.com - September 10 at 8:48 AM
	Cellular Biomedicine Group Announces Dismissal of Class Action Litigation finance.yahoo.com - August 18 at 12:31 PM